Compare · MDLN vs SOLV
MDLN vs SOLV
Side-by-side comparison of Medline Inc. (MDLN) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 3.8x SOLV ($13.51B).
- MDLN has been more active in the news (4 items in the past 4 weeks vs 3 for SOLV).
- MDLN has more recent analyst coverage (25 ratings vs 20 for SOLV).
- Company
- Medline Inc.
- Solventum Corporation
- Price
- -
- -
- Market cap
- $50.91B
- $13.51B
- 1M return
- -
- +3.16%
- 1Y return
- -
- +5.75%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2024
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 20
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest SOLV
- Solventum Corporation filed SEC Form 8-K: Leadership Update
- Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
- BMO Capital Markets initiated coverage on Solventum with a new price target
- Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form SD filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Solventum to Participate in the 2026 Jefferies Healthcare Conference
- Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Alban Carlos
- SEC Form 4 filed by Director Cox Carrie Smith